LQDA is trading 4.3% higher at $78.33, rebounding from the prior session’s decline as it moves back toward recent highs.
- The move appears to be a recovery bounce and sentiment-driven follow-through after recent volatility, as no fresh company-specific news, FDA decisions, or earnings have been reported for June 30, 2026.
- The stock is recovering from a 3.9% drop to $75.12 in the previous session, with broader U.S. indices also trading modestly higher.